We are a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. We aim to achieve this patient-centric mission with a focus on developing a portfolio of highly innovative assets, unconstrained by therapeutic area or technology. Our core operating principle is to make timely, unbiased decisions driven by data and biology. We focus on making the best decisions for each asset without constraints or bias stemming from the needs of other programs in the portfolio. We are confident this unencumbered, asset-centric philosophy has the potential to deliver significant value for all stakeholders.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
November 10, 2022
November 3, 2022